Does OLAPARIB Cause Product dose omission issue? 320 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 320 reports of Product dose omission issue have been filed in association with OLAPARIB (Lynparza). This represents 1.8% of all adverse event reports for OLAPARIB.
320
Reports of Product dose omission issue with OLAPARIB
1.8%
of all OLAPARIB reports
10
Deaths
103
Hospitalizations
How Dangerous Is Product dose omission issue From OLAPARIB?
Of the 320 reports, 10 (3.1%) resulted in death, 103 (32.2%) required hospitalization, and 5 (1.6%) were considered life-threatening.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 320 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which OLAPARIB Alternatives Have Lower Product dose omission issue Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL